Non-hodgkin Lymphoma,B Cell Clinical Trials

17 recruiting

Frequently Asked Questions

Common questions about Non-hodgkin Lymphoma,B Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS1,500 enrolled61 locationsNCT06008691
Recruiting
Phase 1

SynKIR-310 for Relapsed/Refractory B-NHL

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+21 more
Verismo Therapeutics18 enrolled5 locationsNCT06544265
Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS130 enrolled21 locationsNCT06156774
Recruiting
Phase 1

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell
Bioray Laboratories18 enrolled3 locationsNCT05741359
Recruiting
Not Applicable

Universal CAR-T Cell Therapy for NHL

Non-hodgkin Lymphoma,B Cell
Bioray Laboratories6 enrolled1 locationNCT07248163
Recruiting
Phase 2

CAR T-cell Therapy in Patients With Renal Dysfunction

Multiple MyelomaAcute Lymphoblastic Leukemia, AdultNon-hodgkin Lymphoma,B Cell
Northside Hospital, Inc.20 enrolled1 locationNCT05909059
Recruiting
Not Applicable

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell
Swiss Cancer Institute64 enrolled14 locationsNCT06090162
Recruiting
Phase 2

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Non-hodgkin Lymphoma,B Cell
Ryvu Therapeutics SA178 enrolled36 locationsNCT06534437
Recruiting
Early Phase 1

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Non-hodgkin Lymphoma,B Cell
Shanghai Cell Therapy Group Co.,Ltd20 enrolled1 locationNCT06446128
Recruiting
Phase 1Phase 2

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Diffuse Large B Cell LymphomaAcute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in Relapse+4 more
Essen Biotech75 enrolled1 locationNCT06213636
Recruiting
Phase 1Phase 2

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled1 locationNCT06838832
Recruiting
Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

Non-hodgkin Lymphoma,B Cell
Zhejiang University36 enrolled1 locationNCT06716164
Recruiting
Early Phase 1

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia,B-CellNon-hodgkin Lymphoma,B Cell
Zhejiang University20 enrolled1 locationNCT06346912
Recruiting
Phase 1Phase 2

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled2 locationsNCT06321289
Recruiting
Phase 2

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell
Zhejiang University36 enrolled1 locationNCT04661020
Recruiting
Phase 4

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Diffuse Large B Cell LymphomaPrimary CNS LymphomaBurkitt Lymphoma+2 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology300 enrolled1 locationNCT05518383
Recruiting
Early Phase 1

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma,B Cell
Zhejiang University72 enrolled1 locationNCT04532268